Aquatic Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aquatic Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.66M	Sell	15,480 -15,581	-50%	-$4.7M	0.16%	158
2026 Q1	$10.3M	Buy	+31,061	New	+$10.6M	0.3%	84
2025 Q4	–	Sell	-84,059	Closed	-$38.3M	–	1378
2025 Q3	$38.3M	Buy	+84,059	New	+$34.2M	0.71%	22
2025 Q2	–	Sell	-14,348	Closed	-$3.87M	–	1221
2025 Q1	$3.87M	Sell	14,348 -26,204	-65%	-$6.73M	0.1%	265
2024 Q4	$9.54M	Buy	40,552 +20,143	+99%	+$5.3M	0.26%	100
2024 Q3	$5.61M	Buy	20,409 +17,209	+538%	+$4.48M	0.15%	171
2024 Q2	$778K	Sell	3,200 -18,600	-85%	-$2.94M	0.03%	450
2024 Q1	$3.26M	Buy	21,800 +900	+4%	+$150K	0.11%	186
2023 Q4	$4M	Buy	20,900 +3,000	+17%	+$511K	0.1%	204
2023 Q3	$3.17M	Buy	+17,900	New	+$3.42M	0.13%	171
2023 Q2	–	Sell	-21,300	Closed	-$4.27M	–	1297
2023 Q1	$4.27M	Buy	+21,300	New	+$4.48M	0.26%	105
2022 Q2	–	Sell	-200	Closed	-$33K	–	1167
2022 Q1	$33K	Buy	+200	New	+$30.5K	0.05%	373

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's ALNY Position: Q2 2026 in Review

Aquatic Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 50% in Q2 2026, selling an estimated $4.7M and leaving 15,480 shares worth $4.66M. The position accounts for 0.16% of the portfolio, ranked #158.

Aquatic Capital Management first reported a position in ALNY in Q1 2022 and has held it in 12 quarters since. The position peaked at $38.3M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Aquatic Capital Management held 15,480 shares of Alnylam Pharmaceuticals worth $4.66M as of Q2 2026.
Aquatic Capital Management sold 15,581 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.7M.
Alnylam Pharmaceuticals made up 0.16% of Aquatic Capital Management's portfolio in Q2 2026, its #158 holding.
Aquatic Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
Aquatic Capital Management's Alnylam Pharmaceuticals position peaked at $38.3M in Q3 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.